

Practitioner's Docket No. MPI90-002CP2DV1CNBCN3M

USSN: 10/712,332

Preliminary AmendmentIn the Claims:

Please amend claims 1, 2 and 4. Please cancel claims 3 and 5, and add claims 6-12. This listing of the claims replaces all prior versions and listings of claims in the applications:

1. (Currently Amended) A procoagulant composition comprising a transiently inactive modified form of a blood factor selected from the group consisting of Factor Xa, Factor IXa, activated Protein C, and Factor VIIa, or a polypeptide fragment thereof, wherein the blood factor comprises an inhibitor selected from the group consisting of benzamidines, substituted benzamidines, Kunitz class inhibitors, and an antibody or antibody fragment thereof; which wherein the modified blood factor has been transiently modified to have little or no enzymatic activity.
2. (Currently Amended) A blood factor from the group consisting of Factor Xa, Factor IXa, activated Protein C, and Factor VIIa; which has been modified to extend its half-life in serum wherein said modified form of blood factor generates active factor-blood factor in the presence of serum[[.]], wherein the modification is selected from the group consisting of polyethylene glycol conjugation and microencapsulation.
3. (Canceled)
4. (Currently Amended) A pharmaceutical composition for use in treating hemophilia which comprises the modified blood factor of claim [[2]]1 in admixture with a pharmaceutically acceptable excipient.
5. (Canceled)
6. (New) The composition of claim 1, wherein the antibody is a monoclonal antibody.
7. (New) The composition of claim 1, wherein the antibody fragment is a Fab fragment.
8. (New) The composition of claim 1, wherein the inhibitor is a Kunitz class inhibitor.

(Page 2 of 4)

Practitioner's Docket No. MP190-002CP2DV1CNBCN3M

USSN: 10/712,332

9. (New) The composition of claim 8, wherein the inhibitor selected from the group consisting of aprotinin and LACI.

10. (New) The composition of claim 1, wherein the inhibitor is 1,2-bis(5-amidino 2-benzofuranyl)ethane.

11. (New) The pharmaceutical composition of claim 4 for use in treating thrombosis.

12. (New) The composition of claim 11, comprising modified activated Protein C.

(Page 3 of 4)